226 related articles for article (PubMed ID: 34159648)
1. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.
Ardizzone S; Ferretti F; Monico MC; Carvalhas Gabrielli AM; Carmagnola S; Bezzio C; Saibeni S; Bosani M; Caprioli F; Mazza S; Casini V; Cortelezzi CC; Parravicini M; Cassinotti A; Cosimo P; Indriolo A; Di Sabatino A; Lenti MV; Pastorelli L; Conforti F; Ricci C; Sarzi-Puttini P; Vecchi M; Maconi G
J Gastroenterol Hepatol; 2021 Nov; 36(11):3050-3055. PubMed ID: 34159648
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
Berte' R; Mazza S; Stefanucci MR; Noviello D; Costa S; Ciafardini C; Mileti E; Mapelli M; Pasqualato S; Pinto S; Favale A; Vecchi M; Neurath MF; Atreya R; Fantini MC; Facciotti F; Caprioli F
J Crohns Colitis; 2021 May; 15(5):864-868. PubMed ID: 33211810
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F
Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in IBD: The experience of a single tertiary IBD center.
Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
[TBL] [Abstract][Full Text] [Related]
7. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group.
Arrigo S; Alvisi P; Banzato C; Bramuzzo M; Celano R; Civitelli F; D'Arcangelo G; Dilillo A; Dipasquale V; Felici E; Fuoti M; Gatti S; Knafelz D; Lionetti P; Mario F; Marseglia A; Martelossi S; Moretti C; Norsa L; Panceri R; Renzo S; Romano C; Romeo E; Strisciuglio C; Martinelli M
Dig Liver Dis; 2021 Mar; 53(3):283-288. PubMed ID: 33388247
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD.
Berkovitch G; Cohen S; Lubetzky R; Singer D; Yerushalmy-Feler A
BMC Pediatr; 2021 Feb; 21(1):63. PubMed ID: 33541320
[TBL] [Abstract][Full Text] [Related]
9. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.
Maconi G; Bosetti C; De Monti A; Boyapati RK; Shelton E; Piazza N; Carvalhas Gabrielli AM; Lenti MV; Bezzio C; Ricci C; Greco S; Romeo S; Giangregorio F; Gridavilla D; Tagliani F; Massari A; Pastorelli L; Di Sabatino A; Saibeni S; Alicante S; Ferretti F; Rizzardini G; Galli M; Ardizzone S
Dig Liver Dis; 2021 Mar; 53(3):263-270. PubMed ID: 33483259
[TBL] [Abstract][Full Text] [Related]
10. Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?
Hashash JG; Jabak S; Francis FF; Regueiro M
Inflamm Bowel Dis; 2021 Jan; 27(2):291-294. PubMed ID: 32619000
[No Abstract] [Full Text] [Related]
11. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.
Sahyoun LC; Fetene J; McMillan C; Protiva P; Al Bawardy B; Gaidos JKJ; Proctor D
Dig Dis Sci; 2024 May; 69(5):1654-1660. PubMed ID: 38466459
[TBL] [Abstract][Full Text] [Related]
12. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
Creemers RH; Rezazadeh Ardabili A; Jonkers DM; Leers MPG; Romberg-Camps MJ; Pierik MJ; van Bodegraven AA
PLoS One; 2021; 16(10):e0258271. PubMed ID: 34610041
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease.
Martin-Arranz MD; García-Ramírez L; Hernandez-Perez M; Montero Vega D; Martín-Arranz E; Sánchez-Azofra M; Poza Cordon J; Rueda Garcia JL; Noci Belda J; Verges Martínez-Meco T; Blanco San Miguel P; Suarez Ferrer C
Sci Rep; 2023 Apr; 13(1):7044. PubMed ID: 37120662
[TBL] [Abstract][Full Text] [Related]
14. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
[TBL] [Abstract][Full Text] [Related]
15. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study.
Gilissen LPL; Heinen SGH; Rijpma-Jacobs L; Schoon E; Schreuder RM; Wensing AM; van der Ende-van Loon MCM; Bloemen JG; Stapelbroek JM; Stronkhorst A
Clin Exp Med; 2022 Aug; 22(3):465-476. PubMed ID: 34542781
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden.
Ludvigsson JF; Axelrad J; Halfvarson J; Khalili H; Larsson E; Lochhead P; Roelstraete B; Simon TG; Söderling J; Olén O
United European Gastroenterol J; 2021 Mar; 9(2):177-192. PubMed ID: 33704918
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory Bowel Disease Management in a Romanian Tertiary Gastroenterology Center: Challenges of the COVID-19 Pandemic.
Vadan R; Iacob R; Costache R; Stroie T; Saizu IA; Iacob S; Gheorghe L; Diculescu M; Gheorghe C
J Gastrointestin Liver Dis; 2020 Dec; 29(4):549-553. PubMed ID: 33331349
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
[TBL] [Abstract][Full Text] [Related]
19. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
Taxonera C; Sagastagoitia I; Alba C; Mañas N; Olivares D; Rey E
Aliment Pharmacol Ther; 2020 Jul; 52(2):276-283. PubMed ID: 32359205
[TBL] [Abstract][Full Text] [Related]
20. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
